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Opinion statement
Therapeutic options are limited in primary central nervous system lymphoma (PCNSL)
with no uniform consensus on optimal management and few published, randomized tri-
als. High-dose methotrexate in combination with other chemotherapeutic agents forms
the mainstay of treatment. There hasn’t been much progress beyond high-dose meth-
otrexate in this disease, and although results from trials using high-dose chemotherapy
and autologous stem-cell transplant seem promising, these need to be further validat-
ed. Moreover, the role of whole brain radiation in the upfront setting remains to be
determined. However, international efforts in this direction are underway, with ongo-
ing randomized trials in newly diagnosed PCNSL, more research on the molecular path-
ogenesis and biomarkers, and the use of novel agents in salvage therapy. There also is
emphasis on quality of life parameters and neurocognitive status. Future treatment op-
tions should optimize high-efficacy rates while minimizing the risk of neurotoxicity.
Introduction
Primary central nervous system lymphoma (PCNSL) is
an extranodal non-Hodgkin lymphoma (NHL) arising
from the brain, spinal cord, eyes or leptomeninges, in
the absence of prior or concurrent systemic disease.
More than 90 % of PCNSL are diffuse large B-cell lym-
phomas and are sensitive to chemotherapy and radia-
tion. But relapse rates are high with poor long-term
survival compared with other forms of NHL. A minor-
ity of the patients does achieve long-term remission
(95 years) with a potential hope for cure, although laterelapses have been noted. Moreover, long-term survi-
vors are at a risk of delayed neurotoxicity.
Epidemiology
PCNSL accounts for 2.2 % of all primary central ner-
vous system tumors, with a median age of 65 years
at diagnosis [1]. The annual incidence rate is 0.47
cases per 100,000 person-years [1, 2]. Since 2000,
there has been a slight increase in overall incidence,
with a dramatic increase in incidence in the elderly,
particularly those 975 years of age at diagnosis.
Diagnosis
The diagnosis of PCNSL can be made by stereotactic
brain biopsy, cerebrospinal fluid (CSF) cytopathologic
analysis, or by analysis of vitreous aspirate in patients
with ocular involvement. The International PCNSL Col-
laborative Group (IPCG) recommends evaluation for
the extent of disease before initiation of therapy [3].
Prognostic factors
Age and performance status have been consistently
identified to be independently associated with prog-
nosis. Two scoring systems (the International
Extranodal Lymphoma Study Group (IELSG) scoring
system and the Memorial Sloan-Kettering Cancer Cen-
ter prognostic model) currently exist that help serve as
guidelines to determine prognosis and treatment op-
tions in newly diagnosed patients, as well as to stratify
patients to facilitate comparison across clinical trials
[4, 5]. In terms of biomarkers, overexpression of
BCL6 has been shown to be associated with better
prognosis in most studies except a recent study, which
indicated that high BCL6 expression correlated with
poor survival [6, 7, 8￿].
Treatment
The treatment of PCNSL involves use of high-dose methotrexate (HD-MTX)
in varying doses (1–8 g/m
2), used as a single agent or in combination with
other chemotherapeutic agents and/or radiotherapy. There is no consensus
on the dose of HD-MTX or the optimal combination of chemotherapy,
neither is there consensus on the role of radiation in combination with
methotrexate as first-line therapy. There is no role of surgical resection in
treatment of this disease [9].
Radiotherapy
Historically, PCNSL was treated with whole brain radiation (WBRT), which
resulted in high rates of radiographic response but also rapid relapse. WBRT
alone is no longer employed for initial treatment. Also, PCNSL is thought to
be an infiltrating disease and focal RT is not recommended. A multicenter,
phase II trial was conducted in the 1980s in which 41 patients treated with
WBRT to 40 Gy plus a 20 Gy boost to the tumor achieved a median overall
survival (OS) of 12 months, with majority of the recurrences occurring in the
region of the boost [10]. Shibamoto and colleagues reported a median sur-
vival of 18 months in a retrospective analysis of 132 patients treated in the
1990s with WBRT monotherapy at different doses [11]. Later studies dem-
onstrated that high doses of methotrexate could achieve therapeutic con-
centrations in the brain, and when combined with WBRT led to sustained
response [12–15]. Most of these studies used high doses of WBRT up to
45 Gy and some included focal boost. However, there was a high incidence
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studies utilizing lower doses of WBRT. A post-hoc analysis of two phase II
trials utilizing the same induction chemotherapy, but different doses of
WBRT suggested that lowering the dose of consolidation WBRT from 45 to
30.6 Gy led to poor outcomes in patients younger than age 60 years [14].
However, other studies have demonstrated conflicting results. A prospective
study showed no neurocognitive decline after consolidation reduced-dose
WBRT (23.4 Gy) and cytarabine in patients who had achieved a complete
response to induction chemotherapy including HD-MTX [17]. Furthermore,
there was no significant cognitive decline up to 24 months after treatment as
demonstrated by prospective, neuropsychological testing and six of eight
patients were able to return to work [18]. More recently, a retrospective
analysis of varying fields and doses of RT in 33 patients who had achieved a
complete response to HD-MTX containing regimen indicated that higher
WBRT and tumor bed RT doses (940 Gy) do not improve outcome and are
associated with a greater risk of neurotoxicity [19￿]. But, delayed neurotox-
icity from combined modality treatment especially with advancing age and
prolonged progression-free survival (PFS) is well-recognized [20]. Recently,
Correa and colleagues identified 50 PCNSL survivors in remission and found
that those that were treated with HD-MTX and conventional doses of WBRT
had significant neurocognitive dysfunction that interfered with quality of life
and 950 % of these patients were not working due to their illness. On the
contrary, patients that received HD-MTX alone did not have significant
cognitive impairment and had preserved quality of life [21￿].
There has been considerable debate whether adding WBRT to methotrex-
ate-based chemotherapy adds to any benefit in terms of PFS or OS. Omuro et
al. sought to examine the effects of deferring WBRT. Sixty-four patients
younger than age 60 years were treated with a combination of HD-MTX (3 g/
m
2), lomustine, procarbazine, methylprednisolone, and intrathecal metho-
trexate, cytarabine, and methylprednisolone, of whom 54 % had a complete
response and did not receive any further treatment [22]. All other patients
underwent WBRT, high-dose chemotherapy followed by autologous stem cell
transplant, or maintenance chemotherapy. They found that deferring WBRT
affected PFS but not OS. Because salvage WBRT was required, neurotoxicity
was delayed but not eliminated. Another retrospective study of 122 patients
showed no OS benefit in patients who received consolidation treatment with
WBRT compared with those who did not, but higher rates of neurotoxicity
were seen in those who received WBRT [23]. Other retrospective studies had
similar findings [24, 25].
The German PCNSL study group conducted a phase III trial where pa-
tients were randomized to receive HD-MTX–based chemotherapy with or
without WBRT [26￿￿]. A total of 551 patients were enrolled of whom 318
were treated per protocol. The authors reported a median OS of 32.4 months
(95 % confidence interval (CI), 25.8-39) in the cohort receiving WBRT versus
37.1 months (95 % CI, 27.5-46.7) in the cohort that did not receive WBRT as
a part of first-line treatment, with a hazard ratio of 1.06 (95 % CI, 0.8-1.4)
and p value of 0.71. Although the OS was not statistically different in both
groups, the primary hypothesis of non-inferiority of HD-MTX–based regimen
over the same chemotherapy followed by WBRT was not proven due to an
underpowered study (60 % power) and noninferiority margin of 0.9. Serial
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rotoxicity was not possible.
Chemotherapy
High-dose methotrexate forms the backbone of induction chemotherapy for
PCNSL. It is able to achieve cytotoxic levels in the brain parenchyma and CSF
[27, 28]. Various studies have used different doses and schedules of HD-
MTX, but in general, dose ≥3 g/m
2 delivered as an initial bolus followed by
an infusion over 3 hours, administered every 10 to 21 days is recommended
for favorable outcomes and adequate CSF concentrations [25, 29, 30].
There have been various studies using HD-MTX alone or in combination
with other cytotoxic agents and/or WBRT. Concern for WBRT-induced neu-
rotoxicity has led to chemotherapy alone trials.
A multicenter, phase II study of single-agent HD-MTX at 8 g/m
2 given ev-
ery 14 days as induction therapy followed by monthly maintenance cycles
for 12 months in 25 patients yielded an complete response rate (CRR) of
52 % and an overall response rate (ORR) of 74 % with a median PFS of
12.8 months and a median OS of 55.4 months [31, 32]. In another multi-
center trial of 37 patients treated with a maximum of six induction cycles of
HD-MTX at 8 g/m
2, the results were not as compelling. The CRR was 30 %,
median PFS was 10 months, and the median OS was lower than the other
study at 25 months [33]. Studies have demonstrated higher complete re-
sponse proportions in patients who receive more than six induction cycles of
methotrexate-based chemotherapy [17, 31].
Ingeneral,combinationchemotherapyisthoughttoachievehigherresponse
rates with longer durability. A pilot and phase II study of 65 patients was
conducted using HD-MTX at 5 g/m
2 and cytarabine in combination with
dexamethasone, vincristine, vindesine, ifosfamide, cyclophosphamide, and in-
traventricular methotrexate, cytarabine, and prednisolone [34]. The investiga-
tors reported a CRR of 61 %, median PFS of 21 months and median OS of
50months.Atamedianfollowupof100months,32%ofallpatientsand57%
of patients ≤60 years of age were still alive [35]. However, there was a fair
amount of toxicity associated with this regimen; 9 % of patients died and 19 %
developed infections of the Ommaya reservoir. Interestingly, serial
neuropsychologic testing demonstrated no evidence of cognitive decline in the
majorityof the patients. Due to the high rate of Ommaya reservoir infectionsin
the prior trial, the same group conducted another phase II trial with the same
systemicregimenwithout theintraventriculartreatment in18patients[36].The
CRR was 53 %, the median duration of response was only 10 months, and
median PFS was 8 months in all patients, as a result of which the trial was ter-
minated early. The results of this study seem to support a role intraventricular
chemotherapy. However, a retrospective study demonstrated no benefit in OS,
PFS or neurotoxicity of adding intrathecal methotrexate to a HD-MTX–based
regimen [37]. Similar results were found in another retrospective analysis of 69
PCNSL patients with no evidence of positive or suspicious CSF cytology, of
whom 39 received HD-MTX–based chemotherapy (1–3g / m
2 depending on
age)andintrathecalmethotrexate,cytarabine,andmethylprednisolone,andthe
other30receivedthe samesystemicchemotherapywithomissionofintrathecal
treatment [38￿]. The authors found no significant difference in response rates,
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was 28.7 months (95 % CI, 11.1-40.1) in the group receiving intrathecal pro-
phylaxisversus9.9months(95%CI,5.6-27.4)intheothergroup,withapvalue
of 0.0518.
Ferreriandcolleaguesreportedtheresultsfromthefirstsuccessfullycomplet-
ed randomized, phase II trial in PCNSL where 79 patients were treated with
single-agent HD-MTX (3.5 g/m
2 every 21 days) versus HD-MTX and cytarabine
[15]. All patients underwent WBRT after induction chemotherapy. The authors
reported improved efficacy and activity with the addition of cytarabine to
methotrexate and demonstrated that combination chemotherapy is better than
methotrexate monotherapy at this dose and schedule. CRR was 46 % in the
cytarabine plus methotrexate arm versus 18 % in methotrexate monotherapy
arm, and 3-year OS was 46 % and 32 %, respectively.
Intra-arterial delivery of methotrexate in conjunction with blood–brain
barrier disruption has been studied and reported in a series of 149 patients
from multiple institutions [39]. The authors reported an ORR and CRR of
82 % and 58 %, respectively, with a median PFS and OS of 1.8 and 3.1 years,
respectively. Toxicities unique to this method of delivery included peri-pro-
cedural seizures in 33.6 %, carotid or vertebral artery injury in 10.7 %, and
strokes in 7.4 % of the patients.
More recently, rituximab, a chimeric monoclonal antibody targeting CD20
antigen on B-lymphocytes, is being incorporated in combination regimens.
Whenadministeredindosesof375–800mg/m
2,CSFlevelsfrom0.1%to4.4%
of serum levels have been noted on pharmacokinetic studies [17, 40].
Shah et al. demonstrated a CRR of 78 % after 7 cycles of HD-MTX at 3.5 g/
m
2 in combination with rituximab, procarbazine, and vincristine [17]. All
patients underwent WBRT (23.4 vs. 45 Gy depending on response to in-
duction) followed by cytarabine. The estimated 2-year PFS and OS was 57 %
and 67 % after a median follow-up of 37 months.
Rubenstein and colleagues studied the effects of a 2-step dose-intensive
immunochemotherapeutic regimen in a multicenter cooperative group setting
[8￿]. In this trial, 44 patients were treated with induction chemotherapy
consisting of HD-MTX at 8 g/m
2 (day 1), rituximab at 375 mg/m
2 (day 3), and
temozolomide at 150 mg/m
2 (days 7–11). Each of the drugs in the MTR in-
ductionregimenhasbeenstudiedassingleagentswithdemonstratedactivityin
PCNSL. MTR induction was followed by consolidation chemotherapy that in-
cluded intravenous etoposide 5 mg/kg as a continuous infusion over 96 hours
(total 40 mg/kg) and cytarabine at 2 g/m
2 every 12 hours for 8 doses. The CRR
on induction chemotherapy was 66 %. With a median follow-up of 4.9 years,
the 2-year PFS was 57 %, the median PFS was 4 years, and the median OS was
not reached. Major toxicity was grade 4 neutropenia and thrombocytopenia
seen in approximately 50 % of the patients, and the majority of these episodes
were after consolidation chemotherapy. There was one treatment-related death.
These results are encouraging and are comparable to any regimen that includes
WBRT. Moreover, in this study median PFS was similar for older (960 years of
age) and younger patients. This is an interesting finding as prior studies have
shown that patients older than 60 years of age have worse outcomes [5]. The
authors also reported shorter PFS in patients that delayed induction chemo-
therapy beyond 1 month of diagnosis compared to those that did not (3-year
PFS of 20 % vs. 59 %, p=0.05).
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Chemotherapy and radiation have high efficacy rates in PCNSL, but re-
sponses are not durable. Moreover, there is always the issue of neurotoxicity
from radiation. There has been emerging data on the role of high-dose
chemotherapy (HDCT) followed by autologous stem cell transplantation
(ASCT) as first-line therapy for consolidation in PCNSL. Abrey et al. treated
28 patients with HD-MTX and cytarabine for induction followed by treat-
ment with carmustine, etoposide, cytarabine, melphalan (BEAM), and ASCT
[41]. The results were disappointing with a median PFS of 5.6 months for all
patients and 9.3 months for those who underwent ASCT. Subsequently, a
multicenter, phase II trial was conducted in which 25 patients G60 years of
age received induction chemotherapy with HD-MTX, etoposide, carmustine,
and methylprednisolone, then ifosfamide and cytarabine, followed by BEAM
and ASCT, after which patients received WBRT [42]. This study demonstrated
better results with a median PFS of 40 months. More recently, conditioning
regimens have included thiotepa and results have been more encouraging,
likely due to better CNS penetration. In a phase II trial, 23 patients were
treated with HD-MTX followed by high-dose thiotepa/busulfan and ASCT,
and response-adapted WBRT. The median PFS was 17 months [43]. On long-
term follow-up 10 years after initiation of study, the OS rate was 35 %; six
patients remained in complete remission, and the majority of the patients
who did not receive WBRT had no evidence of neurotoxicity [44￿]. Illerhaus
and colleagues treated 43 patients with one of two HD-MTX–based induc-
tion regimens followed by high-dose carmustine/thiotepa and ASCT with/
without WBRT in two prospective trials [45, 46]. They reported a 5-year OS of
70 % and 5-year PFS of 67 % [47]. In a single-center study of 11 patients
treated with HD-MTX and cytarabine, followed by busulfan, cyclophospha-
mide, etoposide, and ASCT, the median PFS was 15 months [48]. Recently,
Illerhaus et al. reported the results of a multicenter study in which 79 patients
were treated with induction HD-MTX, cytarabine, rituximab and thiotepa,
followed by carmustine/thiotepa conditioning before ASCT, with an ORR of
91 % and 2-year OS 87 % [49￿]. Five patients died from the treatment. A
retrospective analysis of 105 patients treated with HDCT followed by ASCT
with/without WBRT demonstrated 5-year OS of 79 % and median PFS and
OS of 85 and 121 months, respectively [50￿]. Based on the results of these
phase II trials, this mode of consolidative treatment seems very promising.
The toxicities, mostly cytopenias, are manageable. There are two ongoing,
multicenter, randomized trials comparing the efficacy of consolidative HDCT
and ASCT versus chemotherapy or WBRT (Table 1).
Treatment in the elderly
The elderlyaccountformore thanhalf ofthe patientswithPCNSL [51].Therisk
of neurotoxicity is the highest in this population, and in general, chemotherapy
alone is a reasonable option. In a study using a HD-MTX–based regimen and
WBRT, almost 90 % of patients 960 years of age developed delayed neurotox-
icityanddiedfromrelatedcomplications,ratherthanrecurrentdisease[52].On
the other hand, almost 50 % of older patients who deferred WBRT died of
progressive disease. Thus, deferring WBRT in older patients reduced treatment-
related neurotoxicity and did not compromise OS. Various studies have indi-
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2 is well tolerated in these patients with
minimalgrade3or4renalandhematologicaltoxicity[53–55].Zhuandcolleagues
reported aseries of 31 patients≥70years of age who were treatedwith amedian of
eight cycles of single-agent HD-MTX at 3.5-8 g/m
2 and demonstrated an ORR of
96.7% with aCRR of 60 % [54]. The median PFS was 7.1 months and median OS
was 37 months. In a retrospective study of 24 patients ≥80 years of age, 23 were
treatedwithHD-MTX–basedregimenwithoutsignificantrenaltoxicitydespitelow
creatinine clearance at baseline and were found to have a 2-year OS of 33 % [56].
Combination chemotherapy has been tried successfully in older patients
and found to be relatively well-tolerated. A phase II trial was conducted in 23
patients 960 years of age who received HD-MTX at 3 g/m
2 (days 1, 10, 20)
and temozolomide at 100 mg/m
2 (days 1–5) followed by up to 5 mainte-
nance monthly cycles of HD-MTX and temozolomide in responders [57]. A
CR was seen in 55 % of the patients, and median PFS and OS were 8 and
35 months, respectively. A multicenter phase II trial of up to six cycles of HD-
MTX (5 g/m
2), lomustine, vincristine, methylprednisolone, and intrathecal
methotrexate and cytarabine in 50 patients with median age of 72 years
(960 years) resulted in a CRR of 42 %, with median PFS and OS of 10.6 and
14.3 months [58]. Illerhaus and colleagues evaluated the effects of three 45-
day cycles of HD-MTX at 3 g/m
2 (days 1, 15, 30) with procarbazine at 60 mg/
m
2 (days 1–10) and lomustine at 110 mg/m
2 (day1) in a phase II trial with
30patients≥65yearsofage[59].CRRwas44.4%,andmedianPFSandOSwere
Table 1. Randomized trials in primary central nervous system lymphoma (PCNSL)
Induction Consolidation
Completed trials Completed trials
1 Ferrerri et al. (IESLG)Ref. 15 Phase II, n=79, age 18–75y
MTX+HD-Ara-C vs. MTX; (followed by WBRT in all), ORR:
69 % vs. 40 % (p=0.009)3y, PFS: 20 % vs. 11 % 3y, OS:
46 % vs. 32 % (p=0.07)
1 Thiel et al. (G-PCNSL-SG-1) Ref. 26 Phase III,
n=318, age918y (MTX±ifosfamide)±WBRT,
mOS: 32.4 vs. 37.1 mo (p=0.71), mPFS:
18.3 vs. 11.9 mo (p=0.14)
2 Omuro et al. (ANOCEF-GOELAMS) Ref. 61 Phase II, n=95,
age≥60y MPV-A vs MT, ORR: 82 % vs. 71 % (p=0.23),
mPFS: 9.5 vs. 6.1 mo (p=0.6), mOS: 31 vs. 13.8
mo (p=0.2)
Ongoing trials Ongoing trials
1 IESLG - NCT01011920 Phase II AM vs. AMR vs. AMRT
(followed by WBRT vs. HDCT+ASCT)
1 IESLG - NCT01011920 Phase II (HD-MTX+Ara-C±R+T)
followed by WBRT vs. HDCT (BT)+ASCT
2 HOVON/ALLG -NTR2427 (Netherlands trial register)
Phase III, open-label MBVP vs. R-MBVP (followed
by Ara-C+WBRT in all)
2 ANOCEF-GOELAMS - NCT00863460 Phase II (R-MBVP,
R-aracytine) followed by WBRT vs. HDCT (TBC)+ASCT
3 RTOG - NCT01399372 Phase II (RMPV-A)±low-dose WBRT
4 CALGB-NCI - NCT01511562 Phase II (MTR-A) followed
by HDCT (BT)+ASCT vs.Ara-C+etoposide
*MTX, high-dose methotrexate; HD-AraC, high-dose cytarabine; WBRT, whole brain radiation therapy; ORR, objective response rate; PFS,
progression-free survival; OS, overall survival; m, median; MPV-A, high-dose methotrexate, procarbazine, vincristine, cytarabine; MT, high-
dose methotrexate, temozolomide; AM, cytarabine, high-dose methotrexate; AMR, cytarabine, high-dose methotrexate, rituximab; AMRT,
cytarabine, high-dose methotrexate, rituximab, thiotepa; HDCT, high-dose chemotherapy; BT, BCNU(carmustine), thiotepa; R-MBVP, ritux-
imab, high-dose methotrexate, BCNU, etoposide or teniposide, prednisone; TBC, thiotepa, BCNU, cyclophosphamide; RMT-A, rituximab,
high-dose methotrexate, temozolomide, cytarabine
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another trial with the addition of rituximab to the same regimen [60]. In 28
patients, the CRR was 64 %, with a median PFS and OS of 16 and 17.5 months
respectively, and 3-year PFS and OS rate of 31 %. Median OS was remarkably
better in patients G80 yearsof age at 29 months, and 4.3 monthsin those older.
There were two treatment-related deaths. The ANOCEF-GOELAMS study was a
multicenter, randomized, phase II trial of chemotherapy alone in elderly pa-
tients with PCNSL [61￿]. In this study, 98 patients were randomized to receive
three cycles of either MPV-A (methotrexate 3.5 g/m
2, days 1 and 15; procarba-
zine 100 mg/m
2,d a y s1 –7; vincristine 1.4 mg/m
2, days 1 and 15) or MT
(methotrexate 3.5 g/m
2, days 1 and 15; temozolomide 100–150 mg/m
2,d a y s
1–5, 15–19) with one additional cycle of cytarabine (3 g/m
2/day for 2 consec-
utive days) in the MPV arm only. While there were trends favoring the MPV-A
regimen over the MT regimen with respect to complete response rate, PFS and
OS, none of these differences reached statistical difference. Recently published
data suggest that the addition of rituximab to both MPV and MT increased the
radiographicresponserate.Bothofthesechemotherapyregimensareoptionsin
elderly PCNSL patients.
Salvage treatment
Despite high response rates seen with initial HD-MTX based treatments,
many patients with PCNSL relapse. Moreover, there is a small subset of pa-
tients that have methotrexate-refractory disease. Prognosis of progressive or
relapsed PCNSL is poor with a limited number of prospective studies for
guidance on management. Rechallenge with HD-MTX has been shown to be
effective in patients that had previously responded to it. In a multicenter
retrospective review of 22 patients, 91 % had a radiographic response to first
salvage treatment with HD-MTX and 100 % to second salvage [62]. The
median OS from first salvage was 61.9 months.
Pemetrexed, which is similar to methotrexate with antifolate activity, has
been shown to been efficacious in recurrent or refractory PCNSL. In a trial of
11 patients who were treated with a median of 5 cycles of pemetrexed at
900 mg/m
2 administered every 3 weeks, there was a ORR of 55 % with 6-
month PFS of 45 % [63￿].
Rituximab and temozolomide have been studied in combination as well
as single agents in relapsed PCNSL. A retrospective review of 17 patients with
single-agent temozolomide demonstrated a median OS of 6.7 months [64].
A prospective study of 36 patients treated with temozolomide reported a
ORR and 1-year OS of 31 % [65]. In a multicenter pilot study of single agent
rituximab in 12 patients, the ORR was 31 % with a median OS of
20.9 months [66￿]. While prior retrospective studies of combination rituxi-
mab and temozolomide demonstrated promising results of ORR of 53-
100 % and 1-year OS of 55 %, a multicenter phase II trial failed to reproduce
the results with early closure of the trial for a poor response rate of 14 % and
median PFS of 7 weeks [67–69]. However, this may have been due to patient
selection bias. Given this regimen is very well tolerated, it is recommended in
a selected population of patients.
Topotecan also has been found to be useful in salvage treatment with re-
sponse rates of 33-40 % and median OS of 8.4 and 35 months in two differ-
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etoposide, ifosfamide, and cytarabine, and procarbazine, lomustine, and vin-
cristine with response rates of 37 % and 86 %, respectively, and 1-year OS of
41 % and 57 %, respectively [72, 73]. Rubenstein and Treseler successfully
treated a patient with intraocular lymphoma with lenalidomide, an
immunomodulating drug (IMiD) [74].
Intraventricular rituximab has been studied by itself and in combination
with intraventricular methotrexate in phase I trials [75, 76]. Fourteen patients
were treated with intraventricular rituximab and methotrexate, of whom 43 %
had a CR in CSF and/or brain [76].
The most impressive results are from a phase II trial conducted by Soussain
andcolleaguesin43patientswhoweretreatedwithinitialhigh-dosecytarabine
and etoposide followed by HDCT with thiotepa, busulfan, cyclophosphamide,
and ASCT [77]. In this study, 27 patients underwent transplantation, of whom
26 had a CR. The median PFS and OS in these 27 patients were 41.1 and
58.6 months, respectively. Kasenda et al. demonstrated that a second
autotransplantation is successful as salvage treatment in patients who have
previously undergone HDCT and ASCT [78].
Allogeneic peripheral blood stem cell transplantation (allo PBSCT) has
been found to be successful in patients with leukemia/lymphoma with
CNS involvement [79–82]. There is one case report in the literature in which
the authors reported a patient with PCSNL who was in complete remission
3 months after the transplantation and remained so for 30 months [83].
Finally, WBRT in patients who have not received it as a part of initial
treatment is an effective option, although there is certainly a risk of neu-
rotoxicity. Many clinicians reserve this for those with chemotherapy-re-
fractory disease in whom the disease has progressed through chemotherapy
at initial treatment or at relapse. In a series of 27 patients treated with WBRT
( m e d i a nd o s e3 6G y ) ,7 4%a c h i e v e dar adiographic response and median
OS was 10.6 months [84]. Late neurotoxicity rates of 15 % were noted at
doses 936 Gy. Another study in 48 patients treated with a median dose of
40 Gy, reported an ORR of 79 % with a median OS of 16 months and
treatment-related neurotoxicity in 22 % of patients [85].
Trials in progress
Although randomized clinical trials have been lacking in the field of
PCNSL, there are now several clinical trials through cooperative groups
investigating various questions regarding optimal treatment strategies
(Table 1) .T h e s es t u d i e sa r ed e s i g n e dt oe xamine the optimal induction
regimen, the role of rituximab in induction, the benefit of consolidative
reduced-dose radiation, as well as comparing high-dose chemotherapy to
myeloablative chemotherapy for consolidation. There are currently two
trials in progress that are comparing consolidative WBRT versus HDCT and
ASCT, both utilizing different conditioning regimens prior to ASCT. Some
of these studies also include correlative biomarkers and imaging compo-
nents as well as assessment of neurocognitive and quality of life outcomes
assessment.
In terms of salvage therapy, novel agents are currently being tested after
their success in systemic B-cell lymphoma. Currently, there are ongoing trials
Treatment of Primary Central Nervous System Lymphoma Nayak and Batchelor 547utilizing the combination of lenalidomide and rituximab (NCT01542918),
single-agent pomalidomide (NCT01722305), and single-agent temsirolimus
(NCT00942747) in treatment of relapsed PCNSL.
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